title: A randomized control study to investigate the application of Ulinastatin-containing contrast medium to prevent post-ERCP pancreatitis.
abstract: OBJECTIVE
  Ulinastatin was reported has positive effects on preventing post-ERCP pancreatitis and hyperamylasemia for patients in average risk. To observe the incidence of post-ERCP pancreatitis and investigate the efficacy and feasibility of using Ulinaststin to prevent post-ERCP pancreatitis.
  
  
  METHODS
  A total of 280 patients were randomized into two arms: an experimental arm using Ulinastatin-containing contrast medium and a control arm using the same contrast medium without Ulinastatin. Blood amylase and urine amylase-2 were measured at three and twenty-four hours after ERCP procedure.
  
  
  RESULTS
  There were distinct differences in the incidence of post-ERCP pancreatitis and average blood amylase levels in the two arms (p < 0.05). Post-ERCP pancreatitis was observed in 20 patients (7.1%), including 7 (4.37%) patients in the experimental arm, and 13 (10.83%) patients in control arm. After 3 hours of the operation, the average blood amylase levels in control and experimental arm were 224.82±34.27 U/L and 189.52±20.94 U/L, respectively. Correspondingly, the levels were 233.59±35.05 U/L and 187.09±23.14 U/L after 24 hours. But the difference was not statistically significant in urine amylase-2 levels, hemoleukocyte count and operation time.
  
  
  CONCLUSIONS
  The exploitation of Ulinastatin in ERCP could decrease the incidence but could not completely prevent the development of post-ERCP pancreatitis.
authors.forename: Jianping
authors.initials: J
authors.lastname: Wang
authors.forename: Jingen
authors.initials: J
authors.lastname: Su
authors.forename: Yining
authors.initials: Y
authors.lastname: Lu
authors.forename: Haihua
authors.initials: H
authors.lastname: Zhou
authors.forename: Biao
authors.initials: B
authors.lastname: Gong
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000681:Amylases / Q000097:blood; D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects*; D003287:Contrast Media; D005260:Female; D006023:Glycoproteins / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000517:prevention & control*
chemical_list: D003287:Contrast Media; D006023:Glycoproteins; D000681:Amylases; C028665:urinastatin